Skip to main content

ADVERTISEMENT

Andrei Pikalov, MD, PhD

Background: Four medications are FDA approved for acute bipolar depression: lurasidone (LUR), cariprazine (CAR), quetiapine IR & XR (QUE), and olanzapine-fluoxetine combination (OFC)....
10/08/2020
Objective: The aim of the current study was to evaluate the long-term safety and effectiveness of lurasidone in pediatric bipolar depression. Method: Patients 10-17 years with bipolar I ...
11/22/2019
Background: The elevated prevalence of metabolic syndrome (MetS) in patients with depression has been associated with increased mortality rates. The aim of this post-hoc analysis was to a...
11/22/2019
Background: In a previous study, dasotraline, a long-acting dopamine/norepinephrine reuptake inhibitor, demonstrated significant efficacy in treatment of binge-eating disorder (BED). We n...
11/22/2019
Background: In a previous study, dasotraline, a long-acting dopamine/norepinephrine reuptake inhibitor, demonstrated efficacy in the treatment of binge-eating disorder (BED). We now repor...
11/22/2019
Objective: To evaluate the efficacy and tolerability of longer-term treatment with lurasidone in patients with major depressive disorder (MDD) with mixed features.
03/01/2019
Objective: To obtain long-term data on the safety and effectiveness of lurasidone in adolescents with schizophrenia Methods: Adolescents (13-17 years) who completed 6 weeks of double-bli...
03/01/2019